论文信息 - A novel entecavir-resistant virus with patient of lamivudine-resistant hepatitis B virus mutant

A novel entecavir-resistant virus with patient of lamivudine-resistant hepatitis B virus mutant

Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine-resistant hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, one patient for whom previous therapies had failed exhibited virologic breakthrough while on ETV. Isolates from this patient were analyzed genotypically for emergent substitutions in HBV reverse transcriptase (RT). After 135 weeks of lamivudine therapy, patient received 0.5 mg of ETV for 52 weeks followed by 1.0 mg of ETV continuously. Viral rebound occurred at 84 weeks after ETV was started. The lamivudine RT substitutions rtH55R, rtL180M and rtM204V were present at study entry, and the additional substitutions rtS202G and rtL269I emerged during ETV treatment.

[1] P. Angus,et al. Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[2] Yoshiyuki Suzuki,et al. Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan , 2003, Intervirology.

[3] William M. Lee,et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.